Cargando…
A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection
Background: In Western countries, breast cancer (BC) is the most common cancer in women. Early detection has a positive impact on survival, quality of life, and public health costs. Mammography screening programs have increased early detection rates, but new approaches to more personalized surveilla...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217920/ https://www.ncbi.nlm.nih.gov/pubmed/37239866 http://dx.doi.org/10.3390/ijms24108520 |
_version_ | 1785048651389730816 |
---|---|
author | Bortul, Marina Giudici, Fabiola Tierno, Domenico Generali, Daniele Scomersi, Serena Grassi, Gabriele Bottin, Cristina Cappelletti, Maria Rosa Zanconati, Fabrizio Scaggiante, Bruna |
author_facet | Bortul, Marina Giudici, Fabiola Tierno, Domenico Generali, Daniele Scomersi, Serena Grassi, Gabriele Bottin, Cristina Cappelletti, Maria Rosa Zanconati, Fabrizio Scaggiante, Bruna |
author_sort | Bortul, Marina |
collection | PubMed |
description | Background: In Western countries, breast cancer (BC) is the most common cancer in women. Early detection has a positive impact on survival, quality of life, and public health costs. Mammography screening programs have increased early detection rates, but new approaches to more personalized surveillance could further improve diagnosis. Circulating cell-free DNA (cfDNA) in blood could provide a potential tool for early diagnosis by analyzing cfDNA quantity, circulating tumor DNA mutations, or cfDNA integrity (cfDI). Methods: Plasma was obtained from the blood of 106 breast cancer patients (cases) and 103 healthy women (controls). Digital droplet PCR was used for the determination of ALU 260/111 bp and LINE-1 266/97 bp copy number ratio and cfDI. cfDNA abundance was calculated using copies of the EEF1A2 gene. The accuracy of biomarker discrimination was analyzed with receiver operating characteristic curve (ROC). Sensitivity analyses were performed to account for age as a potential confounder. Results: Cases had significantly lower ALU 260/111 or LINE-1 266/97 copy number ratios (median; ALU 260/111 = 0.08, LINE-1 266/97 = 0.20), compared with control (median; ALU 260/111 = 0.10, LINE-1 266/97 = 0.28) (p < 0.001). ROC analysis showed that copy number ratio discriminated cases from controls (area under the curve, AUC = 0.69, 95% CI: 0.62–0.76 for ALU and 0.80, 95% CI: 0.73–0.86 for LINE-1). ROC from cfDI confirmed the better diagnostic performance of LINE-1 compared with ALU. Conclusions: Analysis of LINE-1 266/97 copy number ratio or cfDI by ddPCR appears to be a useful noninvasive test that could aid in early BC detection. Further studies in a large cohort are needed to validate the biomarker. |
format | Online Article Text |
id | pubmed-10217920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102179202023-05-27 A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection Bortul, Marina Giudici, Fabiola Tierno, Domenico Generali, Daniele Scomersi, Serena Grassi, Gabriele Bottin, Cristina Cappelletti, Maria Rosa Zanconati, Fabrizio Scaggiante, Bruna Int J Mol Sci Article Background: In Western countries, breast cancer (BC) is the most common cancer in women. Early detection has a positive impact on survival, quality of life, and public health costs. Mammography screening programs have increased early detection rates, but new approaches to more personalized surveillance could further improve diagnosis. Circulating cell-free DNA (cfDNA) in blood could provide a potential tool for early diagnosis by analyzing cfDNA quantity, circulating tumor DNA mutations, or cfDNA integrity (cfDI). Methods: Plasma was obtained from the blood of 106 breast cancer patients (cases) and 103 healthy women (controls). Digital droplet PCR was used for the determination of ALU 260/111 bp and LINE-1 266/97 bp copy number ratio and cfDI. cfDNA abundance was calculated using copies of the EEF1A2 gene. The accuracy of biomarker discrimination was analyzed with receiver operating characteristic curve (ROC). Sensitivity analyses were performed to account for age as a potential confounder. Results: Cases had significantly lower ALU 260/111 or LINE-1 266/97 copy number ratios (median; ALU 260/111 = 0.08, LINE-1 266/97 = 0.20), compared with control (median; ALU 260/111 = 0.10, LINE-1 266/97 = 0.28) (p < 0.001). ROC analysis showed that copy number ratio discriminated cases from controls (area under the curve, AUC = 0.69, 95% CI: 0.62–0.76 for ALU and 0.80, 95% CI: 0.73–0.86 for LINE-1). ROC from cfDI confirmed the better diagnostic performance of LINE-1 compared with ALU. Conclusions: Analysis of LINE-1 266/97 copy number ratio or cfDI by ddPCR appears to be a useful noninvasive test that could aid in early BC detection. Further studies in a large cohort are needed to validate the biomarker. MDPI 2023-05-10 /pmc/articles/PMC10217920/ /pubmed/37239866 http://dx.doi.org/10.3390/ijms24108520 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bortul, Marina Giudici, Fabiola Tierno, Domenico Generali, Daniele Scomersi, Serena Grassi, Gabriele Bottin, Cristina Cappelletti, Maria Rosa Zanconati, Fabrizio Scaggiante, Bruna A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection |
title | A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection |
title_full | A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection |
title_fullStr | A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection |
title_full_unstemmed | A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection |
title_short | A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection |
title_sort | case–control study by ddpcr of alu 260/111 and line-1 266/97 copy number ratio in circulating cell-free dna in plasma revealed line-1 266/97 as a potential biomarker for early breast cancer detection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217920/ https://www.ncbi.nlm.nih.gov/pubmed/37239866 http://dx.doi.org/10.3390/ijms24108520 |
work_keys_str_mv | AT bortulmarina acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT giudicifabiola acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT tiernodomenico acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT generalidaniele acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT scomersiserena acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT grassigabriele acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT bottincristina acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT cappellettimariarosa acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT zanconatifabrizio acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT scaggiantebruna acasecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT bortulmarina casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT giudicifabiola casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT tiernodomenico casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT generalidaniele casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT scomersiserena casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT grassigabriele casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT bottincristina casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT cappellettimariarosa casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT zanconatifabrizio casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection AT scaggiantebruna casecontrolstudybyddpcrofalu260111andline126697copynumberratioincirculatingcellfreednainplasmarevealedline126697asapotentialbiomarkerforearlybreastcancerdetection |